慢性丙型肝炎直接抗病毒药物的研究进展和应用前景

针对HCV感染的标准治疗方案是聚乙二醇干扰素α联合利巴韦林。按此治疗方案部分HCV感染者是可治愈的。但仍有一小部分患者不能治愈。随着分子生物学的进展,针对HCV生活周期中病毒蛋白靶向特异性治疗的许多小分子化合物的研究得到了迅速发展,提高了抗病毒的疗效。这些药物统一命名为抗HCV的直接抗病毒药物(direct-acting antiviralagents,DAAs),包括非结构蛋白(non-structural protein,NS)3/4A蛋白酶抑制剂、NS5B聚合酶抑制剂和NS5A蛋白抑制剂等。本文对慢性丙型肝炎DAAs的研究进展、临床应用、应用中的问题及应用前景进行概述。

Recent progress and future prospects of direct-acting antiviral agents for chronic hepatitis C

The current standard treatment for HCV infection is the combination of pegylated interferon-alpha and ribavirin.HCV infection is curable in some patients with the current standard treatment,however,it remains incurable in a small number of HCV patients.Recent advances in molecular biology have led to the development of a large number of new agents for chronic hepatitis C to enhance the curative rate,which target specific HCV enzymes in HCV life cycle.These agents,collectively termed as direct-acting antiviral agents(DAAs) against HCV,include a range of non-structural protein(NS) 3/NS4A protease inhibitor,NS5B polymerase inhi-bitor and NS5A inhibitors.This review focuses on the research progress,clinical application,the problems in clinical practice and the future applications of the DAAs for chronic hepatitis C.